Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

829
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
829
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teaming up for welfare: a cross-institute approach to identify robust indicators of emotion in pigs.

Animal : an international journal of animal bioscience·2026
Same author

Viscoelastic profiling of rare pediatric extracranial tumors using multifrequency MR elastography: a pilot study.

Scientific reports·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

Cytotoxicity of metal-containing carbon monoxide-releasing molecules: A current assessment.

Journal of inorganic biochemistry·2026
Same author

Determinants of Microscale pH in In Situ-Grown Dental Biofilms.

Journal of dental research·2023
Same author

Corrigendum to "Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines" [Exp. Cell Res. 375 (2019) 92-99].

Experimental cell research·2023
Same journal

[Renale Outcomes bei Kindern mit neurogener Blase: Anatomische und urodynamische Determinanten jenseits des Uropathogentyps].

Klinische Padiatrie·2026
Same journal

[Impact of the COVID-19 pandemic on voiding diary quality and its relevance for the treatment of functional urinary incontinence in children].

Klinische Padiatrie·2026
Same journal

Guidance for the Diagnosis and Treatment of Rare Embryonal and Sarcomatous Brain Tumors-a Report from the Central Nervous System-International Registry for Rare Embryonal and Sarcomatous Tumors German Society of Pediatric Oncology and Hematology Study Group.

Klinische Padiatrie·2026
Same journal

Klinische Padiatrie·2026
Same journal

Association of Fat-free Mass Index and Body Mass Index on Pulmonary Function Tests in Children with Rheumatological Disease-associated Interstitial Lung Disease.

Klinische Padiatrie·2026
Same journal

Synchronous Differentiated Thyroid Carcinoma and Nonthyroid Malignancies in Pediatric Patients: A Registry-based Case Series.

Klinische Padiatrie·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

11.6K

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

J H Schulte1, S Schulte, L C Heukamp

  • 1German Cancer Consortium (DKTK), Germany.

Klinische Padiatrie
|October 30, 2013
PubMed
Summary
This summary is machine-generated.

Anaplastic lymphoma kinase (ALK) inhibitors show promise for treating high-risk neuroblastoma, a challenging childhood cancer. New ALK inhibitors are being tested in pediatric patients to improve survival rates.

More Related Videos

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

10.9K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Experiment Videos

Last Updated: May 6, 2026

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

11.6K
Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
09:45

Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis

Published on: March 31, 2015

10.9K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Area of Science:

  • Pediatric Oncology
  • Molecular Targeted Therapy
  • Cancer Genetics

Background:

  • Neuroblastoma, a common childhood extracranial tumor, exhibits variable aggressiveness based on disease subtypes.
  • High-risk neuroblastoma and relapsed cases present significant treatment challenges, necessitating novel therapeutic strategies.
  • Activating mutations in anaplastic lymphoma kinase (ALK) are the most prevalent druggable mutations in neuroblastoma.

Purpose of the Study:

  • To evaluate the efficacy of anaplastic lymphoma kinase (ALK) inhibitory therapy in neuroblastoma.
  • To assess the potential of ALK inhibitors as a new treatment option for pediatric neuroblastoma patients.
  • To introduce the availability of second-generation ALK inhibitors for pediatric patients.

Main Methods:

  • Preclinical studies demonstrating neuroblastoma cell dependence on mutated ALK.
  • Phase I clinical trials of the first-generation ALK inhibitor, Crizotinib, in pediatric patients.
  • Initiation of an international Phase I study for a second-generation ALK inhibitor, LDK-378.

Main Results:

  • Preclinical data indicate that ALK inhibition effectively targets neuroblastoma models.
  • Early-phase clinical testing of Crizotinib yielded encouraging antitumoral responses in neuroblastoma patients.
  • The study paves the way for broader access to ALK inhibitors in pediatric oncology.

Conclusions:

  • Targeting anaplastic lymphoma kinase (ALK) mutations represents a promising therapeutic avenue for neuroblastoma.
  • ALK inhibitors, including Crizotinib and LDK-378, offer new hope for improving survival in pediatric neuroblastoma.
  • Continued investigation and clinical trials are crucial for optimizing ALK-targeted therapies in neuroblastoma treatment.